Spero Therapeutics Target of Unusually Large Options Trading (NASDAQ:SPRO)

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock traders bought 1,962 call options on the company. This is an increase of approximately 3,988% compared to the typical volume of 48 call options.

Spero Therapeutics Price Performance

NASDAQ:SPRO traded down $0.22 during trading hours on Thursday, reaching $2.13. The company had a trading volume of 7,326,795 shares, compared to its average volume of 944,611. Spero Therapeutics has a 1-year low of $0.51 and a 1-year high of $2.48. The firm has a market cap of $119.09 million, a PE ratio of 30.43 and a beta of 0.23. The business's 50 day moving average price is $0.74 and its 200-day moving average price is $0.88.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.55) by $0.30. Spero Therapeutics had a return on equity of 4.03% and a net margin of 3.30%. The company had revenue of $5.87 million during the quarter, compared to the consensus estimate of $11.00 million. On average, analysts expect that Spero Therapeutics will post -1.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of SPRO. Monimus Capital Management LP acquired a new position in Spero Therapeutics in the fourth quarter valued at approximately $320,000. Virtu Financial LLC acquired a new position in Spero Therapeutics in the fourth quarter valued at approximately $47,000. Prudential Financial Inc. acquired a new position in shares of Spero Therapeutics during the 4th quarter worth approximately $51,000. JPMorgan Chase & Co. raised its stake in shares of Spero Therapeutics by 26,011.9% during the 4th quarter. JPMorgan Chase & Co. now owns 61,624 shares of the company's stock worth $63,000 after buying an additional 61,388 shares during the period. Finally, ADAR1 Capital Management LLC raised its stake in shares of Spero Therapeutics by 7.8% during the 4th quarter. ADAR1 Capital Management LLC now owns 801,277 shares of the company's stock worth $825,000 after buying an additional 57,818 shares during the period. 25.60% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "buy" rating and set a $5.00 target price on shares of Spero Therapeutics in a report on Thursday, January 30th.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.